奥氮平联合草酸艾司西酞普兰治疗冠心病支架植入后以躯体不适症状为典型表现抑郁症的临床研究  

Clinical Study of Olanzapine Combined with Escitalopram Oxalate in the Treatment of Depression with Typical Somatic Symptoms after Coronary Stent Implantation

作　　者：赖文文 卢辉耀[1] 蔡克锋[1] 许朝祥[1] 张志龙 黄明伟 LAI Wenwen;LU Huiyao;CAI Kefeng;XU Chaoxiang;ZHANG Zhilong;HUANG Mingwei(The Second Affiliated Hospital of Fujian Medical University,Quanzhou 362000,China;不详)

机构地区：[1]福建医科大学附属第二医院,福建泉州362000

出　　处：《中外医学研究》2021年第28期5-8,共4页CHINESE AND FOREIGN MEDICAL RESEARCH

基　　金：福建医科大学启航基金项目(2019QH1124)。

摘　　要：目的:观察奥氮平联合草酸艾司西酞普兰治疗冠心病支架植入后发生的以躯体不适症状为典型表现抑郁症患者的临床效果。方法:连续纳入福建医科大学附属第二医院2019年2月-2021年1月105例PCI术后以躯体不适症状为典型表现的抑郁症患者,随机数字表法分为观察组(51例)和对照组(54例),对照组采用口服草酸艾司西酞普兰方案,观察组采用奥氮平联合草酸艾司西酞普兰联合方案,疗程12周。比较服药前后两组患者精神障碍症状自评量表(SCL-90)躯体化因子评分、汉密尔顿抑郁量表(HAMD-24)评分及生存质量评分变化,记录药物不良反应。结果:观察组治疗8、12周SCL-90躯体化因子评分、HAMD-24评分均显著低于对照组(P<0.05);观察组治疗8、12周WHOQOL-BREF生理领域、心理领域、社会关系领域评分均显著高于对照组(P<0.05);观察组体重增加>10%的患者比例为11.76%,显著高于对照组的1.85%(P<0.05)。结论:以躯体不适症状为典型表现抑郁症患者采用草酸艾司西酞普兰治疗PCI术后基础上加用奥氮平,能进一步减轻躯体症状与抑郁程度,改善生活质量,但会明显增加患者体重。Objective:To observe the efficacy of Olanzapine combined with Escitalopram Oxalate the treatment of depression with typical somatic symptoms after coronary stent implantation.Method:A total of 105 depression patients with typical somatic symptoms after PCI from February 2019 to January 2021 of the Second Affiliated Hospital of Fujian Medical University were enrolled,and they were randomly divided into the observation group(51 cases)and the control group(54 cases)according to the random number method.The control group was administrated with Escitalopram Oxalate,the observation group was treated with Olanzapine combined with Escitalopram Oxalate,treatment course was 12 weeks,two groups of SCL-90 somatization score,HAMD-24 depression score and life quality score were compared before and after treatment,and adverse drug reactions were recorded.Result:The scores of SCL-90 somatization factor and HAMD-24 in the observation group were significantly lower than those in the control group at 8 and 12 weeks of treatment(P<0.05).The scores of WHOQOL-BREF in physiological field,psychological field and social relationship field in the observation group were significantly higher than those in the control group at 8 and 12 weeks of treatment(P<0.05).The proportion of patients with weight gain>10% in the observation group was 11.76%,which was significantly higher than 1.85% in the control group(P<0.05).Conclusion:Based on Escitalopram Oxalate in the treatment of depression after PCI,Olanzapine added in patients with depression with typical somatic symptoms can further reduce somatic symptoms and depression,improve the quality of life,but significantly increase the weight gain.

关 键 词：PCI 躯体症状 抑郁症 草酸艾司西酞普兰 奥氮平 

分 类 号：R749.4[医药卫生—神经病学与精神病学]